Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01391611 · ClinicalTrials.gov registry record · Phase 2
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
A Phase 2 study, sponsored by Kristen Ganjoo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01391611 is a Phase 2 study that was terminated before completion, run by Kristen Ganjoo. The registered enrollment target is 25 participants.
The verdict
NCT01391611, a Phase 2 study, was terminated before completion, sponsored by Kristen Ganjoo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is being done to gather information about the safety (any harmful effects) and effectiveness (usefulness) of Pazopanib in the treatment of Gastrointestinal Stroma Tumors (GIST) that cannot be treated by surgery or has spread to other organs. The Food and Drug Administration (FDA) have approved Pazopanib for the treatment of advanced kidney cancer but it is not approved for the treatment of GIST. The investigators hope to learn about the safety and usefulness (effectiveness) of Pazopanib for patients with GIST. Primary Objective: Non-progression rate based on RECIST criteria (CR+PR+SD) Secondary Objectives: * Response per Choi criteria * 6 month progression-free survival * Safety and tolerability
Interventions
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01391611
The ClinicalTrials.gov registry entry for NCT01391611 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kristen Ganjoo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib is the first listed.
NCT01391611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01391611 about?
NCT01391611 is a clinical study titled "Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)". This study is being done to gather information about the safety (any harmful effects) and effectiveness (usefulness) of Pazopanib in the treatment of Gastrointestinal Stroma Tumors (GIST) that cannot be treated by surgery or has spread to other organs. The Food and Drug Administration (FDA) have app...
What is the current status of trial NCT01391611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-07. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01391611?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01391611?
This trial is sponsored by Kristen Ganjoo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.